HDFC Securities has come out with its third quarter (October-December) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Dr. Reddy’s Labs to report net profit at 380 crore up 28.4% quarter-on-quarter. Net Sales are expected to increase by 4.6 percent Q-o-Q (down 5.4 percent Y-o-Y) to Rs 3750 crore, according to HDFC Securities. Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 23.5 percent Q-o-Q (down 26.7 percent Y-o-Y) to Rs 740 crore.
You can also follow us for daily intraday updates click here to SUBSCRIBE US http://www.ripplesadvisory.com/free-trial.php
HDFC Securities has come out with its third quarter (October-December) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Dr. Reddy’s Labs to report net profit at 380 crore up 28.4% quarter-on-quarter. Net Sales are expected to increase by 4.6 percent Q-o-Q (down 5.4 percent Y-o-Y) to Rs 3750 crore, according to HDFC Securities. Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 23.5 percent Q-o-Q (down 26.7 percent Y-o-Y) to Rs 740 crore.
No comments:
Post a Comment